IL6 and COVID-19: Notably, IP-10, together with IL-6 and IL-10, is reported to constitute a severity-related triad that anticipates subsequent clinical progression (specifically) in COVID-19 patients, but not in non-COVID-19 patients with lower respiratory tract infections [36].